Journal of Neurochemistry · 2003 · 198 citations · 45 references
Life SciencesNeurosciencePharmacologyClinical PharmacologyNeurodegenerationNeuropharmacologyAmyotrophic Lateral SclerosisMitochondrial DysfunctionNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAmyotrophic Lateral Sclerosis ModelsCyclooxygenase InhibitorsCyclooxygenase PathwaysCyclooxygenase-2 PathwayMotor PerformanceNeuroprotective AgentsNeuroprotective PharmacotherapyTransgenic Mouse Models
There is substantial evidence implicating both inflammation and mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS) pathogenesis. We investigated the therapeutic effects of cyclooxygenase 2 (COX-2) inhibitors both alone and in combination with creatine in the G93A transgenic mouse model of ALS. Oral administration of either celecoxib or rofecoxib significantly improved motor performance, attenuated weight loss and extended survival. The administration of COX-2 inhibitors significantly reduced prostaglandin E2 levels at 110 days of age. The combination of creatine with COX-2 inhibitors produced additive neuroprotective effects and extended survival by approximately 30%. The COX-2 inhibitors significantly protected against depletion of anterior horn motor neurons and creatine with COX-2 inhibitors showed greater protection than COX-2 inhibitors alone. These results suggest that combinations of therapies targeting different disease mechanisms may be a useful strategy in the treatment of ALS.
45
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Paola Bezzi, Giorgio Carmignoto, Lucia Pasti et al. · Nature · 1998 · 1.1K citations
Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model
Mingwei Li, Victor Ona, Christelle Guégan et al. · Science · 2000 · 716 citations